PHARMAFIN
InactiveInactive; last annual accounts for fiscal year 2024.
Signals
Two signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Annual accounts not filed
The financial year that closed on 30-09-2025 was due at the National Bank by 30-04-2026. Nothing is on record, 153 days later.
NBB · 2 filingsPosition against the passed deadline
30-09-2025 close30-04-2026 deadline30-09-2026 today
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2024 was due by 30-04-2025 and was filed on 23-12-2024, 128 days ahead of the deadline.
NBB · 2 filingsDeviation from the deadline
2025
not filed
2024
128 d early
2023
14 d early
← before the deadline
after the deadline →
tick = median of all Belgian filings
This company filed its last 2 accounts on average 71 days before the deadline; the Belgian median for financial year 2024 is 4 days before the deadline, and 38% of all filings were late.
Checked, nothing found (1)
Financials · fiscal year 2024, micro schema
Equity
€899,335▲ 78.8%
2023 · €502,993
Total assets
€1.2m▲ 77.4%
2023 · €651,380
Net result
€431,084▲ 336%
2023 · €98,868
Working capital
€899,077▲ 2,511%
2023 · €34,430
Trend over the years
Click a name to add, emphasise or remove a line.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20232024
Operating result€142,862-€510,372▲ 257%
Net result€98,868-€431,084▲ 336%
Equity€502,993-€899,335▲ 78.8%
Total assets€651,380-€1.2m▲ 77.4%
Debt€148,387-€256,087▲ 72.6%
Working capital€34,430-€899,077▲ 2,511%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result rises in 2024; 2024 is 257% above 2023.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €1.2m
Fixed assets
€258 ▼ 99.9%
Current assets
€1.2m ▲ 532%
Equity and liabilities €1.2m
Equity
€899,335 ▲ 78.8%
Debt
€256,087 ▲ 72.6%
Debt's share of the balance-sheet total falls from 22.8% to 22.2%. Equity and debt are higher.
Key figures and ratios
EBITDA
€510,620▲
2023 · €143,110
Cash flow
€431,332▲
2023 · €99,116
Current ratio
4.51▲
2023 · 1.23
Debt to equity
0.28▼
2023 · 0.30
ROE
47.9%▲
2023 · 19.7%
ROA
37.3%▲
2023 · 15.2%
Interest coverage
11023.74▲
2023 · 40.89
Debt ≤ 1 year
€256,087▲
2023 · €148,387
Income taxes
€93,631▲
2023 · €40,494
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2023 | 2024 | Change |
|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €248 | €248 | = |
| Other operating charges640/8 | €1,446 | €640 | ▼ 55.8% |
| Gross operating margin9900 | €144,556 | €511,259 | ▲ 254% |
| Operating profit (loss)9901 | €142,862 | €510,372 | ▲ 257% |
| Financial income75/76B | - | €14,390 | - |
| Recurring financial income75 | - | €14,390 | - |
| Financial charges65/66B | €3,500 | €46 | ▼ 98.7% |
| Recurring financial charges65 | €3,500 | €46 | ▼ 98.7% |
| Profit (loss) for the period before taxes9903 | €139,362 | €524,715 | ▲ 277% |
| Income taxes67/77 | €40,494 | €93,631 | ▲ 131% |
| Profit (loss) for the period9904 | €98,868 | €431,084 | ▲ 336% |
| Profit (loss) for the period to be appropriated9905 | €98,868 | €431,084 | ▲ 336% |
| Line | 2023 | 2024 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €651,380 | €1.2m | ▲ 77.4% |
| Fixed assets21/28 | €468,563 | €258 | ▼ 99.9% |
| Tangible fixed assets22/27 | €506 | €258 | ▼ 49.0% |
| Plant, machinery and equipment23 | €506 | €258 | ▼ 49.0% |
| Financial fixed assets28 | €468,058 | - | - |
| Current assets29/58 | €182,816 | €1.2m | ▲ 532% |
| Amounts receivable within one year40/41 | - | €24,319 | - |
| Trade receivables40 | - | €24,319 | - |
| Current investments50/53 | €27,520 | €38,030 | ▲ 38.2% |
| Cash at bank and in hand54/58 | €155,296 | €1.1m | ▲ 604% |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €651,380 | €1.2m | ▲ 77.4% |
| Equity10/15 | €502,993 | €899,335 | ▲ 78.8% |
| Contributions10/11 | €74,000 | €74,000 | = |
| Reserves13 | €428,993 | €825,335 | ▲ 92.4% |
| Non-distributable reserves130/1 | €7,400 | - | - |
| Reserves not available under the articles1311 | €7,400 | - | - |
| Distributable reserves133 | €421,593 | €825,335 | ▲ 95.8% |
| Amounts payable17/49 | €148,387 | €256,087 | ▲ 72.6% |
| Amounts payable within one year42/48 | €148,387 | €256,087 | ▲ 72.6% |
| Trade debts44 | €20,260 | €76,241 | ▲ 276% |
| Suppliers440/4 | €20,260 | €76,241 | ▲ 276% |
| Taxes, remuneration and social security45 | €25,206 | €77,408 | ▲ 207% |
| Taxes450/3 | €24,193 | €75,205 | ▲ 211% |
| Remuneration and social security454/9 | €1,013 | €2,204 | ▲ 118% |
| Other amounts payable47/48 | €102,921 | €102,438 | ▼ 0.5% |
| Line | 2023 | 2024 | Change |
|---|---|---|---|
| Profit (loss) for the period9904 | €98,868 | €431,084 | ▲ 336% |
| + Depreciation and write-downs630 | €248 | €248 | = |
| Operating cash flow (approximation) | €99,116 | €431,332 | ▲ 335% |
| Investment in fixed assets (approximation) | - | €468,058 | - |
| Change in cash | - | €937,519 | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2024
23-12
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
30-09
Financial
Liquidity quadruplescurrent ratio 4.51
Current ratio from 1.23 to 4.51.
16-04
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 3 acts read
About the unread acts
We know of 3 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Structure & network
Owners and holdings
1 holdingOwners 0
The accounts to 30-09-2024 list no shareholders, and no other source names one.
Holdings 1
-
100%
According to the annual accounts to 30-09-2024 of PHARMAFIN and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No current directors or connected companies found in the register.